• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从肿瘤免疫抑制到根除:靶向免疫效应细胞归巢至肿瘤及其在肿瘤中的活性

From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.

作者信息

Draghiciu Oana, Nijman Hans W, Daemen Toos

机构信息

Department of Medical Microbiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.

出版信息

Clin Dev Immunol. 2011;2011:439053. doi: 10.1155/2011/439053. Epub 2011 Dec 8.

DOI:10.1155/2011/439053
PMID:22190971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3235497/
Abstract

Unraveling the mechanisms used by the immune system to fight cancer development is one of the most ambitious undertakings in immunology. Detailed knowledge regarding the mechanisms of induction of tolerance and immunosuppression within the tumor microenvironment will contribute to the development of highly effective tumor eradication strategies. Research within the last few decades has shed more light on the matter. This paper aims to give an overview on the current knowledge of the main tolerance and immunosuppression mechanisms elicited within the tumor microenvironment, with the focus on development of effective immunotherapeutic strategies to improve homing and activity of immune effector cells to tumors.

摘要

揭示免疫系统对抗癌症发展所使用的机制是免疫学中最具挑战性的任务之一。关于肿瘤微环境中诱导耐受和免疫抑制机制的详细知识将有助于制定高效的肿瘤根除策略。过去几十年的研究使人们对这一问题有了更深入的了解。本文旨在概述肿瘤微环境中引发的主要耐受和免疫抑制机制的当前知识,重点是开发有效的免疫治疗策略,以改善免疫效应细胞向肿瘤的归巢和活性。

相似文献

1
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.从肿瘤免疫抑制到根除:靶向免疫效应细胞归巢至肿瘤及其在肿瘤中的活性
Clin Dev Immunol. 2011;2011:439053. doi: 10.1155/2011/439053. Epub 2011 Dec 8.
2
Overcoming tumor-mediated immunosuppression.克服肿瘤介导的免疫抑制。
Immunotherapy. 2014;6(9):973-88. doi: 10.2217/imt.14.58.
3
Improving cancer immunotherapy by targeting tumor-induced immune suppression.通过靶向肿瘤诱导的免疫抑制来改善癌症免疫疗法。
Cancer Metastasis Rev. 2011 Mar;30(1):125-40. doi: 10.1007/s10555-011-9280-5.
4
[Immune system and tumors].[免疫系统与肿瘤]
Ann Pathol. 2017 Feb;37(1):11-17. doi: 10.1016/j.annpat.2016.12.004. Epub 2017 Jan 31.
5
Nanoparticles for tumor immunotherapy.用于肿瘤免疫治疗的纳米颗粒。
Eur J Pharm Biopharm. 2017 Jun;115:243-256. doi: 10.1016/j.ejpb.2017.03.013. Epub 2017 Mar 18.
6
Editorial: Novel Strategies for Cancer Immunotherapy: Targeting Immune-Mediated Suppressive Mechanisms.社论:癌症免疫疗法的新策略:靶向免疫介导的抑制机制
Front Immunol. 2021 May 3;12:691899. doi: 10.3389/fimmu.2021.691899. eCollection 2021.
7
Targeting regulatory T cells in tumors.靶向肿瘤中的调节性T细胞。
FEBS J. 2016 Jul;283(14):2731-48. doi: 10.1111/febs.13656. Epub 2016 Mar 1.
8
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.获得性癌症免疫疗法耐药性:肿瘤介导免疫抑制的作用。
Semin Cancer Biol. 2020 Oct;65:13-27. doi: 10.1016/j.semcancer.2019.07.017. Epub 2019 Jul 27.
9
A fresh look at tumor immunosurveillance and immunotherapy.肿瘤免疫监视与免疫治疗新视角。
Nat Immunol. 2001 Apr;2(4):293-9. doi: 10.1038/86297.
10
Need for immunologic stimulators during immunosuppression produced by major cancer surgery.在大型癌症手术所致免疫抑制期间对免疫刺激剂的需求。
Ann Surg. 1985 Jul;202(1):9-20. doi: 10.1097/00000658-198507000-00002.

引用本文的文献

1
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.靶向纳米药物重塑免疫抑制性肿瘤微环境以增强癌症免疫治疗。
Acta Pharm Sin B. 2022 Dec;12(12):4327-4347. doi: 10.1016/j.apsb.2022.11.001. Epub 2022 Nov 4.
2
Morphine suppresses the immune function of lung cancer by up-regulating MAEL expression.吗啡通过上调 MAEL 表达抑制肺癌的免疫功能。
BMC Pharmacol Toxicol. 2022 Dec 7;23(1):92. doi: 10.1186/s40360-022-00632-z.
3
Factors Influencing False-Negative Results of QuantiFERON-TB Gold In-Tube (QFT-GIT) in Active Tuberculosis and the Desirability of Resetting Cutoffs for Different Populations: A Retrospective Study.影响活动性结核病中管内QuantiFERON-TB Gold(QFT-GIT)检测假阴性结果的因素及针对不同人群重新设定临界值的必要性:一项回顾性研究
Trop Med Infect Dis. 2022 Sep 30;7(10):278. doi: 10.3390/tropicalmed7100278.
4
Acid Microenvironment in Bone Sarcomas.骨肉瘤中的酸性微环境
Cancers (Basel). 2021 Jul 30;13(15):3848. doi: 10.3390/cancers13153848.
5
Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines.抗PD-1和抗CTLA-4抗体联合诱导在肾癌细胞系的DC-CIK细胞中具有协同抗肿瘤作用。
Int J Clin Exp Pathol. 2019 Jan 1;12(1):123-132. eCollection 2019.
6
Morphine and ketamine treatment suppress the differentiation of T helper cells of patients with colorectal cancer .吗啡和氯胺酮治疗可抑制结直肠癌患者T辅助细胞的分化。
Exp Ther Med. 2019 Jan;17(1):935-942. doi: 10.3892/etm.2018.7035. Epub 2018 Nov 29.
7
An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.基于甲病毒的治疗性癌症疫苗:从设计到临床试验。
Cancer Immunol Immunother. 2019 May;68(5):849-859. doi: 10.1007/s00262-018-2276-z. Epub 2018 Nov 21.
8
Hypoxia and acidosis: immune suppressors and therapeutic targets.缺氧和酸中毒:免疫抑制剂和治疗靶点。
Immunology. 2018 Jul;154(3):354-362. doi: 10.1111/imm.12917. Epub 2018 Mar 30.
9
Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.基于感染增强腺病毒载体和促炎性同种异体树突状细胞组合的癌症疫苗在三种黑色素瘤模型中引发持续的抗原特异性免疫反应。
Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018.
10
Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer.低剂量辐射可增加胃癌中过继性细胞毒性T淋巴细胞的迁移。
Exp Ther Med. 2017 Dec;14(6):5711-5716. doi: 10.3892/etm.2017.5305. Epub 2017 Oct 13.

本文引用的文献

1
Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.调节性T细胞在涉及重组甲病毒载体系统的免疫策略中的作用。
Antivir Ther. 2011;16(2):207-18. doi: 10.3851/IMP1751.
2
Cyclophosphamide induces differentiation of Th17 cells in cancer patients.环磷酰胺诱导癌症患者中 Th17 细胞的分化。
Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9.
3
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.选择性耗竭 Foxp3+调节性 T 细胞可提高建立的黑色素瘤有效治疗性疫苗的疗效。
Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5.
4
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.用病毒体和甲病毒复制子疫苗进行异源初免-加强免疫。
Mol Pharm. 2011 Feb 7;8(1):65-77. doi: 10.1021/mp1002043. Epub 2010 Sep 23.
5
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
6
Myeloid-derived suppressor cells in human cancer.人类癌症中的髓源性抑制细胞。
Cancer J. 2010 Jul-Aug;16(4):348-53. doi: 10.1097/PPO.0b013e3181eb3358.
7
Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth.肿瘤浸润巨噬细胞产生的白细胞介素-10 在人乳头瘤病毒 16 肿瘤生长中发挥作用。
BMC Immunol. 2010 Jun 7;11:27. doi: 10.1186/1471-2172-11-27.
8
Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells.上皮性卵巢癌诱导的 CD11b(+)Gr-1(+)细胞的抗原特异性免疫和交叉呈递。
J Immunol. 2010 Jun 1;184(11):6151-60. doi: 10.4049/jimmunol.0903519. Epub 2010 Apr 28.
9
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.舒尼替尼通过分区限制直接和差异抑制髓源性抑制细胞亚群。
Cancer Res. 2010 May 1;70(9):3526-36. doi: 10.1158/0008-5472.CAN-09-3278. Epub 2010 Apr 20.
10
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.5-氟尿嘧啶选择性杀死肿瘤相关的髓系来源的抑制性细胞,从而增强 T 细胞依赖性抗肿瘤免疫。
Cancer Res. 2010 Apr 15;70(8):3052-61. doi: 10.1158/0008-5472.CAN-09-3690. Epub 2010 Apr 13.